<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363971">
  <stage>Registered</stage>
  <submitdate>3/04/2013</submitdate>
  <approvaldate>19/04/2013</approvaldate>
  <actrnumber>ACTRN12613000455763</actrnumber>
  <trial_identification>
    <studytitle>Botulinum toxin injection for vocal cord dysfunction in asthma</studytitle>
    <scientifictitle>Botulinum toxin injection for vocal cord dysfunction in asthma - benefits on symptoms and laryngeal imaging</scientifictitle>
    <utrn>N/A</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <healthcondition>Vocal cord dysfunction</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Botulinum toxin injection of unilateral vocal cord. 
Injection done in 3 ways: through skin under electromyography, through the skin under endoscopic guidance and direct injection under general anesthetic.
Dose 2.5-5U per injection.
Observation for 3 months.
Repeat injection after 1-3 months if symptoms recurrent (ACT score same or lower than baseline).
Injection technique was at the discretion of the ENT surgeon and doses were based on his experience injecting vocal cord dystonias (&gt;300 cases).</interventions>
    <comparator>No comparator used</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Asthma Control Test Score one month after injection.</outcome>
      <timepoint>One month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Degree of vocal cord dysfunction detected on Computerised Tomography (CT) imaging of the larynx after one month.</outcome>
      <timepoint>One month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Side efftects immediately after injection, formally after one month and after 3 months. This entailed a history of known possible side-effects (loss of voice, dysphagia, choking, cough) as well as any spontaneous adverse symptoms.</outcome>
      <timepoint>Three months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Difficult-to-treat asthma unresponsive to optimised treatments,
Vocal cord dysfunction on imaging,
ACT score &lt;15</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to botulinum toxin
Other known laryngeal disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Although a treatment was given no specific allocation was done. Sequential patients were enrolled at the discretion of the investigators. There was no concealment of allocation.
Patients were selected and enrolled from a severe asthma clinic, treatment given and patient outcomes prospectively collected.  The study is can therefore be viewed as interventional since a treatment was given and outcomes were monitored.
</concealment>
    <sequence>N/A - see above.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Unblinded, proof-of-concept study, no power calculations done.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/07/2012</anticipatedstartdate>
    <actualstartdate>28/08/2012</actualstartdate>
    <anticipatedenddate>1/04/2013</anticipatedenddate>
    <actualenddate>5/03/2013</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
    <postcode>3168 - Clayton</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Monash Medical Centre</primarysponsorname>
    <primarysponsoraddress>246 Clayton Rd
Clayton, Victoria, 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Monash Lung &amp; Sleep, Monash Medical Centre</fundingname>
      <fundingaddress>Monash Medical Centre
246 Clayton Rd
Clayton, Victoria, 3168</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aims to provide proof-of-concept support for the use of botulinum toxin in difficult-to-treat asthma with vocal cord dysfunction.</summary>
    <trialwebsite>N/A</trialwebsite>
    <publication>N/A</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>N/A</publicnotes>
    <ethicscommitee>
      <ethicname>Southern Health Therapeutics/Ethics Committee</ethicname>
      <ethicaddress>Monash Medical Centre
246 Clayton Rd
Clayton, Victoria, 3168</ethicaddress>
      <ethicapprovaldate>27/08/2012</ethicapprovaldate>
      <hrec>SHTC-08-12</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Southern Health Research Ethics Committee</ethicname>
      <ethicaddress>Monash Medical Centre
246 Clayton Rd, Clayton, Victoria, 3168</ethicaddress>
      <ethicapprovaldate>16/01/2013</ethicapprovaldate>
      <hrec>13004Q</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Philip Bardin</name>
      <address>Monash Medical Centre
246 Clayton Rd
Clayton, Victoria, 3168</address>
      <phone>61 3 95942281</phone>
      <fax>61 3 95946415</fax>
      <email>philip.bardin@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Joanne McKenzie</name>
      <address>Clinical Trials Coordinator
Monash Lung &amp; Sleep
246 Clayton Rd
Clayton, Victoria, 3168</address>
      <phone>61 3 95942279</phone>
      <fax>61 3 95946415</fax>
      <email>joanne.mckenzie@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Philip Bardin</name>
      <address>Monash Lung &amp; Sleep
Monash Medical Centre
246 Clayton Rd
Clayton, Victoria, 3168</address>
      <phone>61 3 95942281</phone>
      <fax>61 3 95946415</fax>
      <email>philip.bardin@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Philip Bardin</name>
      <address>Monash Lung &amp; Sleep
Monash Medical Centre
246 Clayton Rd
Clayton 3168</address>
      <phone />
      <fax />
      <email>philip.bardin@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>